Table 3 Concomitant diagnoses at baseline by system organ class
MedDRA preferred term | ||
|---|---|---|
Medical history | Tiotropium | Placebo |
Number of patients | 238 (100) | 219 (100) |
Number of patients with ≥1 disease or syndrome | 190 (79.8) | 179 (81.7) |
Blood and lymphatic system disorders | 0 (0.0) | 2 (0.9) |
Cardiac disorders | 30 (12.6) | 24 (11.0) |
Congenital, familial and genetic disorders | 0 (0.0) | 1 (0.5) |
Ear and labyrinth disorders | 2 (0.8) | 9 (4.1) |
Endocrine disorders | 16 (6.7) | 13 (5.9) |
Eye disorders | 12 (5.0) | 12 (5.5) |
Gastrointestinal disorders | 41 (17.2) | 43 (19.6) |
General disorders and administration site conditions | 1 (0.4) | 2 (0.9) |
Hepatobiliary disorders | 5 (2.1) | 1 (0.5) |
Immune system disorders | 22 (9.2) | 17 (7.8) |
Infections and infestations | 4 (1.7) | 7 (3.2) |
Injury poisoning and procedural complications | 1 (0.4) | 4 (1.8) |
Investigations | 4 (1.7) | 5 (2.3) |
Metabolism and nutritional disorders | 69 (29.0) | 86 (39.3) |
Musculoskeletal and connective tissue disorders | 72 (30.3) | 64 (29.2) |
Neoplasms benign, malignant, unspecified | 0 (0.0) | 0 (0.0) |
Nervous system disorders | 23 (9.7) | 28 (12.8) |
Psychiatric disorders | 32 (13.4) | 22 (10.0) |
Renal and urinary disorders | 6 (2.5) | 10 (4.6) |
Reproductive system and breast disorders | 18 (7.6) | 20 (9.1) |
Respiratory, thoracic and mediastinal disorders | 16 (6.7) | 8 (3.7) |
Skin and subcutaneous tissue disorders | 11 (4.6) | 11 (5.0) |
Social circumstances | 3 (1.3) | 3 (1.4) |
Surgical and medical procedures | 6 (2.5) | 3 (1.4) |
Vascular disorders | 105 (44.1) | 118 (53.9) |
